5T4 inhib 
Welcome,         Profile    Billing    Logout  
 8 Companies  6 Products   6 Products   2 Diseases   8 Trials   107 News 
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Clinical, P1 data, Journal:  Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. (Pubmed Central) -  May 22, 2021   
    P1
    It remains to be seen if this vaccination strategy generates immune responses of sufficient magnitude to mediate clinical efficacy and whether it can be effective in late-stage PCa settings, as a monotherapy in advanced disease or as part of multi-modality PCa therapy. To address these questions, the phase I/II trial, ADVANCE, is currently recruiting patients with intermediate-risk PCa, and patients with advanced metastatic castration-resistant PCa, to receive this vaccine in combination with nivolumab.
  • ||||||||||  Review, Journal:  LRR-Containing Oncofetal Trophoblast Glycoprotein 5T4 Shapes Neural Circuits in Olfactory and Visual Systems. (Pubmed Central) -  Nov 18, 2020   
    Single-cell transcriptomics further suggests that 5T4 is involved in the development and maintenance of functional synapses in a subset of retinal interneurons, including rod bipolar cells (RBCs) and amacrine cells (ACs). Collectively, 5T4, expressed in interneurons of the OB and retina, plays a key role in sensory processing in the olfactory and visual systems.
  • ||||||||||  ZV-05 / Sorrento, ZovaBio
    Journal:  Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker. (Pubmed Central) -  May 13, 2020   
    A novel cytotoxic payload called Duostatin-5 (Duo-5) which was derived from monomethyl auristatin F (MMAF) was attached to a 5T4 targeting antibody (ZV05) by interchain cysteine cross-linking conjugation via a disubstituted C-Lock linker...The superior in vivo activity of ZV0508 may be due to the combined use of the disubstituted C-Lock linker and the novel payload Duo-5, resulting in a more stable and potent ADC. Taken together, these data suggest ZV0508 is a worthy candidate for the treatment of 5T4 positive cancers.
  • ||||||||||  Journal:  Improved Inhibition of Tumor Growth by Diabody-Drug Conjugates via Half-Life Extension. (Pubmed Central) -  Feb 20, 2020   
    In a xenograft model of breast cancer MDA-MB-436, the ABD-diabody-PBD showed greater tumor growth suppression and better tolerability than either PEG-diabody-PBD or diabody-PBD. These results suggest that the mechanism of half-life extension is an important consideration for designing cytotoxic anti-tumor agents.
  • ||||||||||  Journal:  WAIF1 is a cell-surface CTHRC1 binding protein coupling bone resorption and formation. (Pubmed Central) -  Oct 27, 2019   
    Unexpectedly, osteoblast lineage-specific deletion of Tpbg downregulated Rankl expression in mouse bones and reduced both bone formation and resorption; importantly, it impaired bone mass recovery following RANKL-induced resorption, reproducing the phenotype of osteoclast-specific Cthrc1 deficiency. Thus, the binding of osteoclast-derived CTHRC1 to WAIF1 in stromal cells activates PKC?-ERK osteoblastogenic signaling and serves as a key molecular link between bone resorption and formation during bone remodeling.
  • ||||||||||  DuoBody®-CD3x5T4 shows potent preclinical anti-tumor activity in vitro and in vivo in a range of cancer indications (Prince George's Exhibition Halls AB) -  Oct 2, 2019 - Abstract #SITC2019SITC_1139;    
    DuoBody-CD3x5T4 is a bispecific antibody that induces CD4+ and CD8+ T-cell activation, cytokine production and T-cell-mediated cytotoxicity of 5T4-expressing tumor cells in vitro and in vivo. Due to its mechanism of action, the broad expression of 5T4 across cancer indications and limited expression in normal cells, DuoBody-CD3x5T4 is a promising novel drug candidate with potential anti-tumor effect across different solid tumors.
  • ||||||||||  Journal:  Expression of Oncofetal Antigen 5T4 in Murine Taste Papillae. (Pubmed Central) -  Aug 17, 2019   
    Notably, X-ray irradiation enhanced cell proliferation more in 5T4-knockout mice than in WT mice. Our results suggest that 5T4, expressed in epithelial progenitors (taste stem/progenitor cells), and taste precursor cells, may influence the maintenance of taste papillae under both normal and injury conditions.
  • ||||||||||  Journal:  Lipopolysaccharide-initiated persistent rhinitis causes gliosis and synaptic loss in the olfactory bulb. (Pubmed Central) -  Jun 28, 2019   
    In the OB, we observed activation of microglia and astrocytes and decreased expression of tyrosine hydroxylase in periglomerular cells, vesicular glutamate transporter 1, a presynaptic protein, in mitral and tufted projection neurons, and 5T4 in granule cells. Thus, the OM inflammation exerted a detrimental effect, not only on OSNs, but also on OB neurons, which might lead to neurodegeneration.